·SEC EDGARLow
Farrell Michael J. sold $1.2M of RMD
Farrell Michael J. (Chairman and CEO) sold 4,993 shares of RESMED INC (RMD) at $235.35 ($1.18M total) on 2026-11-09 under a Rule 10b5-1 trading plan.
StockNYSE · US · USDHealthcare · Medical Instruments & Supplies
$RMD
RESMED INC
ResMed designs and supplies medical devices, diagnostic products and software for sleep and breathing health, serving patients, clinicians, healthcare providers and residential care organizations. Its Sleep and Breathing Health segment offers CPAP, APAP and bilevel devices, ventilators, high flow therapy systems, masks, headgear, accessories, dental devices, diagnostic products and connected-care software. Products include AirSense, AirCurve and AirMini devices, and myAir and AirView applications. ResMed also operates VirtuOx, which facilitates in-home and remote testing for sleep, respiratory, cardiac and other health conditions in the United States, and owns Noctrix Health, which makes a device for restless legs syndrome. Its Residential Care Software segment provides cloud-based software for billing, clinical records, revenue cycle management, analytics, patient engagement and workforce management. Brands include Brightree and MEDIFOX DAN; ResMed has agreed to sell its MatrixCare business. ResMed sells products in more than 140 countries through subsidiaries and independent distributors and employs approximately 11,370 people. Its headquarters are in San Diego, California.
AlphAI earnings readFirst Quarter of Fiscal Year 2027 · OCT 29Q1 revenue increased by 6% to $1.4 billion; GAAP diluted earnings per share up 23% to $2.92; non-GAAP diluted EPS up 14% to $2.91Verdict: solidRead →
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
Price · $RMDvia TradingView
AI sentiment · 7d0 articles
No enriched coverage for $RMD in the last 7 days.
Insider · 30dAll trades →
- Buys
- — 0 txs
- Sells
- $1.3M 2 txs
Rider Michael J1× · $102K
10b5-1 share of filings100%
Top stories · $RMDMore →
·tradingview.com
Canaccord Genuity downgrades ResMed to Hold from Buy
Canaccord Genuity downgraded ResMed from Buy to Hold. Recent analyst price targets for ResMed range from $250 to $288.
·finance.yahoo.com
What Sent ResMed Stock Lower?
ResMed (RMD) shares dropped 9.1% on October 30, 2026, following its fiscal Q1 2027 earnings release. The company beat earnings and revenue estimates, with EPS of $2.91 and revenue of $1.41B. Despite 14% higher EPS YoY, revenue growth slowed to 5.9%. Peers also fell, with Stryker (SYK) down 6.4% after missing estimates. The broader market declined due to AI sector selloff. ResMed's stock is down 8.4% over the past year.
RMD sentiment & insider activity
Recent RMD coverage spans financial news, earnings and insider activity.
In the last 30 days, RMD insiders filed 2 SEC Form 4 transactions — no purchases and 2 sales ($1.3M). The most active reporter was Rider Michael J, Global General Counsel, with 1 filing. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.
What's driving RMD
The insider sale may signal modest confidence concerns, but the amount is relatively small for a large‑cap company.
The downgrade signals reduced confidence in near‑term growth, likely prompting short‑term selling.
The earnings beat was offset by the weakest revenue growth in five quarters, prompting a sharp sell‑off.
Analyst target raise suggests upside potential for ResMed.
The stock experienced a sharp intraday decline with no disclosed catalyst.
AlphAI scores every news story that mentions RMD with an AI model for sentiment and relevance, and aggregates insider trades from RESMED INC's SEC EDGAR Form 4 filings. Figures refresh continuously.
News on $RMD
Score
Farrell Michael J. sold $1.2M of RMD
Farrell Michael J. (Chairman and CEO) sold 4,993 shares of RESMED INC (RMD) at $235.35 ($1.18M total) on 2026-11-09 under a Rule 10b5-1 trading plan.
Canaccord Genuity downgrades ResMed to Hold from Buy
Canaccord Genuity downgraded ResMed from Buy to Hold. Recent analyst price targets for ResMed range from $250 to $288.
What Sent ResMed Stock Lower?
ResMed (RMD) shares dropped 9.1% on October 30, 2026, following its fiscal Q1 2027 earnings release. The company beat earnings and revenue estimates, with EPS of $2.91 and revenue of $1.41B. Despite 14% higher EPS YoY, revenue growth slowed to 5.9%. Peers also fell, with Stryker (SYK) down 6.4% after missing estimates. The broader market declined due to AI sector selloff. ResMed's stock is down 8.4% over the past year.
Citigroup maintains ResMed at Neutral, raises price target to $270 from $240
Citigroup kept its Neutral rating on ResMed but increased its price target to $270 from $240, suggesting a 17.4% upside from the last close. Other recent analyst targets for ResMed range from $250 to $288.
ResMed Inc. stock falls Friday, underperforms market
ResMed Inc. shares declined 9.05% to $229.94 on Friday, underperforming broader market indices. The S&P 500 and Dow Jones fell 1.82% and 1.09%, respectively. The stock is now 17.19% below its 52-week high of $277.67.
RBC Capital maintains ResMed at Outperform, raises price target to $288 from $262
RBC Capital kept its Outperform rating on ResMed and raised its price target to $288 from $262, suggesting a 13.9% upside from the Oct 29 close of $252.83, according to the firm.
Wells Fargo maintains ResMed at Equal-Weight, raises price target to $250 from $215
Wells Fargo kept ResMed's rating at Equal-Weight but increased its price target to $250 from $215, suggesting a 1.1% downside from the last close. The bank cited a 16.3% increase in the target.
ResMed (RMD) Q1 2027 Earnings Call Transcript
ResMed (RMD) reported Q1 2027 earnings, highlighting innovation in sleep health products, including new bilevel devices and fabric masks. The company saw a 6% increase in therapy adherence with fabric masks and 4.3% with AI-driven Smart Comfort. ResMed also improved gross margins and expanded U.S. manufacturing. The myAir app, with 13M+ downloads, enhances patient engagement and compliance.
Keybanc maintains ResMed at Overweight, raises price target to $277 from $267
Keybanc reaffirmed its Overweight rating for ResMed and increased its price target from $267 to $277, suggesting a 9.6% upside from the last close of $252.83.
ResMed (NYSE:RMD) posts better-than-expected sales in Q3 CY2026
ResMed reported Q3 CY2026 revenue of $1.41 billion, exceeding estimates by 1.7% and growing 5.9% year-on-year. Adjusted EPS was $2.91, an 8.9% beat. Operating and free cash flow margins declined slightly from the prior year.